228 patents
Page 5 of 12
Utility
Human Cytomegalovirus Vaccine
31 Mar 22
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 10 Dec 21
Utility
Mrna Combination Therapy for the Treatment of Cancer
31 Mar 22
The present disclosure relates to the use of nucleic acid (e.g., mRNA) combination therapies for the treatment of cancer.
Joshua P. FREDERICK, Susannah HEWITT, Ailin BAI, Stephen G. HOGE, Vladimir PRESNYAK, Iain MCFADYEN, Kerry BENENATO, Ellalahewage Sathyajith KUMARASINGHE
Filed: 16 Mar 21
Utility
Compositions and methods for delivery of agents
29 Mar 22
This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins.
Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
Filed: 11 Oct 19
Utility
Zika virus RNA vaccines
22 Mar 22
The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof.
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks
Filed: 16 Apr 20
Utility
CorrectedBroad Spectrum Influenza Virus Vaccine
17 Mar 22
The disclosure relates to broad spectrum influenza virus ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccine.
Giuseppe Ciaramella, Eric Yi-Chun Huang, Kerim Babaoglu, Jessica Anne Flynn, Lan Zhang, David Nickle
Filed: 15 Mar 18
Utility
Polynucleotides Encoding Citrin for the Treatment of Citrullinemia Type 2
10 Mar 22
The invention relates to mRNA therapy for the treatment of Citrullinemia Type 2 (“CTLN2”). mRNAs for use in the invention, when administered in vivo, encode human Citrin, isoforms thereof, functional fragments thereof, and fusion proteins comprising Citrin. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of Citrin expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of biomarkers associated with deficient Citrin activity in subjects, namely ammonia and/or triglycerides.
Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Jingsong Cao, Lin Tung Guey, Staci Sabnis
Filed: 21 Jan 21
Utility
Crystal Forms of Amino Lipids
10 Mar 22
Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (“Compound 1”), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (“Compound 2”), (3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (“Compound 3”), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (“MC3”), and related compositions and methods.
Orn ALMARSSON, Eugene CHEUNG
Filed: 12 Nov 21
Utility
Human Cytomegalovirus Vaccine
3 Mar 22
Aspects of the disclosure relate to methods for producing an antigen-specific immune response to human cytomegalovirus (hCMV) in a subject by administering mRNA vaccines.
Jack F. Kramarczyk, Kimberly Hassett, Shinu John, Phil White, Andrea Carfi
Filed: 25 Aug 21
Utility
Methods of Preparing Lipid Nanoparticles
3 Mar 22
The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof.
Mike SMITH, Allen HORHOTA, Jason AUER, Brie SKINNER
Filed: 31 Jan 20
Utility
Modified Mrna for the Treatment of Progressive Familial Intrahepatic Cholestasis Disorders
24 Feb 22
The present disclosure provides compositions of nucleic acids relating to biliary epithelial transporters.
Paolo Martini, Vladimir Presnyak, Jingsong CAO
Filed: 13 Sep 19
Utility
High-purity Peg Lipids and Uses Thereof
3 Feb 22
The present disclosure is based, at least in part, on the discovery that high-purity PEG lipids exhibit superior physical and biological properties, particularly when used in lipid nanoparticle (LNP) formulations.
Örn Almarsson, Jin Lim, Eugene Cheung, Jaclyn Milton
Filed: 19 Sep 19
Utility
Chikungunya virus RNA vaccines
1 Feb 22
The disclosure relates to tropical diseases such as viral mosquito borne illnesses and the treatment thereof.
Giuseppe Ciaramella, Sunny Himansu, Eric Yi-Chun Huang, Tal Zaks, Sayda Mahgoub Elbashir
Filed: 21 Apr 20
Utility
CorrectedInfluenza Vaccine
27 Jan 22
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use ribonucleic acid vaccines comprising polynucleotide molecules encoding one or more influenza antigens, such as hemagglutinin antigens.
Giuseppe Ciaramella
Filed: 18 Dec 20
Utility
Compounds and compositions for intracellular delivery of therapeutic agents
11 Jan 22
The disclosure features novel lipids and compositions involving the same.
Kerry E. Benenato, Mark Cornebise
Filed: 29 Aug 19
Utility
Use of Mrna Encoding OX40L to Treat Cancer In Human Patients
6 Jan 22
The disclosure features methods for treating ovarian cancer, as well as other cancers such as solid tumors, lymphomas and epithelial origin cancers, by administering mRNA encoding an OX40L polypeptide.
Robert MEEHAN, Sima ZACHAREK, Kristen HOPSON, Joshua P. FREDERICK
Filed: 8 Nov 19
Utility
Zika virus mRNA vaccines
28 Dec 21
Provided herein, in some embodiments, are Zika virus RNA vaccines and methods of producing an antigen-specific immune response in a subject.
Giuseppe Ciaramella, Sunny Himansu
Filed: 14 Apr 20
Utility
Rna Polymerase Variants
23 Dec 21
The present disclosure provides, in some aspects, variant RNA polymerases, the use of which increases transcription efficiency while reducing the number of double-stranded RNA contaminates and run-on transcripts produced during an in vitro transcription reaction.
Amy E. Rabideau, Athanasios Dousis, Kanchana Ravichandran, Elissa Hobert
Filed: 17 Jun 21
Utility
High purity RNA compositions and methods for preparation thereof
21 Dec 21
The invention relates to improved RNA compositions for use in therapeutic applications.
Stephen Hoge, William Issa, Edward J. Miracco, Jennifer Nelson, Amy E. Rabideau, Gabor Butora
Filed: 14 Sep 17
Utility
Crystal forms of amino lipids
21 Dec 21
Provided herein are novel solid forms of each of four compounds: (1) heptadecan-9-yl 8-((2-hydroxyethyl)amino)octanoate (“Compound 1”), (2) heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (“Compound 2”), (3) heptadecan-9-yl 8-((2-hydroxyethyl)(8-(nonyloxy)-8-oxooctyl)amino)octanoate (“Compound 3”), and (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (“MC3”), and related compositions and methods.
Orn Almarsson, Eugene Cheung
Filed: 15 Mar 18
Utility
Delivery and Formulation of Engineered Nucleic Acids
16 Dec 21
Provided are formulations, compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression.
Antonin DE FOUGEROLLES, Sayda M. ELBASHIR
Filed: 5 Jan 21